Omnicell (OMCL)
Market Price (8/19/2026): $35.95 | Market Cap: $1.6 BilSector: Health Care | Industry: Health Care Technology
Omnicell (OMCL)
Market Price (8/19/2026): $35.95Market Cap: $1.6 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10% Attractive yieldFCF Yield is 7.7% Megatrend and thematic driversMegatrends include Automation & Robotics, and Digital Health & Telemedicine. Themes include Process / Warehouse Automation, AI in Healthcare Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -118% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/EPrice/Earnings or Price/(Net Income) is 42x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% Key risksOMCL key risks include [1] a dependence on a limited number of suppliers for critical components and technology, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10% |
| Attractive yieldFCF Yield is 7.7% |
| Megatrend and thematic driversMegatrends include Automation & Robotics, and Digital Health & Telemedicine. Themes include Process / Warehouse Automation, AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -118% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/EPrice/Earnings or Price/(Net Income) is 42x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.1% |
| Key risksOMCL key risks include [1] a dependence on a limited number of suppliers for critical components and technology, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/3/2026
Omnicell (OMCL) stock has lost about 15% since 4/30/2026 because of the following key factors:
1. Softer-than-expected Third Quarter Fiscal 2026 Guidance: Omnicell's stock experienced a significant decline after the company issued third quarter fiscal 2026 guidance that fell below analyst expectations. The company projected revenue between $301 million and $307 million, which was below the consensus estimate of $312.6 million. Similarly, diluted earnings per share (EPS) guidance of $0.35 to $0.43 missed the analyst consensus of $0.43. This cautious near-term outlook overshadowed strong second quarter performance.
2. Concerns over Sustainability of Profitability Due to One-Time Tariff Refund: While Omnicell reported robust non-GAAP diluted earnings per share of $0.94 for fiscal Q2 2026, these results included a $15 million one-time tariff refund. This refund significantly boosted non-GAAP EBITDA and gross margin. Excluding this benefit, non-GAAP EBITDA would have been approximately $52 million, raising investor concerns about the underlying, sustainable profitability of the company moving forward.
Show more
Omnicell (OMCL) stock has lost about 15% since 4/30/2026 because of the following key factors:
1. Softer-than-expected Third Quarter Fiscal 2026 Guidance: Omnicell's stock experienced a significant decline after the company issued third quarter fiscal 2026 guidance that fell below analyst expectations. The company projected revenue between $301 million and $307 million, which was below the consensus estimate of $312.6 million. Similarly, diluted earnings per share (EPS) guidance of $0.35 to $0.43 missed the analyst consensus of $0.43. This cautious near-term outlook overshadowed strong second quarter performance.
2. Concerns over Sustainability of Profitability Due to One-Time Tariff Refund: While Omnicell reported robust non-GAAP diluted earnings per share of $0.94 for fiscal Q2 2026, these results included a $15 million one-time tariff refund. This refund significantly boosted non-GAAP EBITDA and gross margin. Excluding this benefit, non-GAAP EBITDA would have been approximately $52 million, raising investor concerns about the underlying, sustainable profitability of the company moving forward.
Show more
Updated on 8/3/2026
Omnicell (OMCL) stock has lost about 15% since 4/30/2026 because of the following key factors:
1. Softer-than-expected Third Quarter Fiscal 2026 Guidance: Omnicell's stock experienced a significant decline after the company issued third quarter fiscal 2026 guidance that fell below analyst expectations. The company projected revenue between $301 million and $307 million, which was below the consensus estimate of $312.6 million. Similarly, diluted earnings per share (EPS) guidance of $0.35 to $0.43 missed the analyst consensus of $0.43. This cautious near-term outlook overshadowed strong second quarter performance.
2. Concerns over Sustainability of Profitability Due to One-Time Tariff Refund: While Omnicell reported robust non-GAAP diluted earnings per share of $0.94 for fiscal Q2 2026, these results included a $15 million one-time tariff refund. This refund significantly boosted non-GAAP EBITDA and gross margin. Excluding this benefit, non-GAAP EBITDA would have been approximately $52 million, raising investor concerns about the underlying, sustainable profitability of the company moving forward.
3. Uncertainty in Bookings Timing and Slower Annual Recurring Revenue (ARR) Growth: Management indicated increased uncertainty regarding the timing of large and medium product bookings, leading to a widened guidance range. Furthermore, the company updated its full-year fiscal 2026 annual recurring revenue (ARR) expectations, noting that some growth initiatives were taking longer to ramp than previously anticipated. This updated outlook for ARR is now expected to be between $660 million and $680 million.
4. Analyst Price Target Reductions Following Earnings: Post-earnings release, several analyst firms adjusted their outlook on Omnicell. Keybanc, for instance, maintained an "Overweight" rating but lowered its price target from $70.00 to $65.00 on July 31, 2026, reflecting a more cautious sentiment. Wells Fargo also lowered its price target to $50 from $55.
Show less
Omnicell (OMCL) stock has lost about 15% since 4/30/2026 because of the following key factors:
1. Softer-than-expected Third Quarter Fiscal 2026 Guidance: Omnicell's stock experienced a significant decline after the company issued third quarter fiscal 2026 guidance that fell below analyst expectations. The company projected revenue between $301 million and $307 million, which was below the consensus estimate of $312.6 million. Similarly, diluted earnings per share (EPS) guidance of $0.35 to $0.43 missed the analyst consensus of $0.43. This cautious near-term outlook overshadowed strong second quarter performance.
2. Concerns over Sustainability of Profitability Due to One-Time Tariff Refund: While Omnicell reported robust non-GAAP diluted earnings per share of $0.94 for fiscal Q2 2026, these results included a $15 million one-time tariff refund. This refund significantly boosted non-GAAP EBITDA and gross margin. Excluding this benefit, non-GAAP EBITDA would have been approximately $52 million, raising investor concerns about the underlying, sustainable profitability of the company moving forward.
3. Uncertainty in Bookings Timing and Slower Annual Recurring Revenue (ARR) Growth: Management indicated increased uncertainty regarding the timing of large and medium product bookings, leading to a widened guidance range. Furthermore, the company updated its full-year fiscal 2026 annual recurring revenue (ARR) expectations, noting that some growth initiatives were taking longer to ramp than previously anticipated. This updated outlook for ARR is now expected to be between $660 million and $680 million.
4. Analyst Price Target Reductions Following Earnings: Post-earnings release, several analyst firms adjusted their outlook on Omnicell. Keybanc, for instance, maintained an "Overweight" rating but lowered its price target from $70.00 to $65.00 on July 31, 2026, reflecting a more cautious sentiment. Wells Fargo also lowered its price target to $50 from $55.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -13.2% change in OMCL stock from 4/30/2026 to 8/18/2026 was primarily driven by a -95.4% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 41.42 | 35.97 | -13.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,185 | 1,247 | 5.2% |
| Net Income Margin (%) | 0.2% | 3.1% | 1710.1% |
| P/E Multiple | 907.3 | 42.0 | -95.4% |
| Shares Outstanding (Mil) | 45 | 46 | -1.4% |
| Cumulative Contribution | -13.2% |
Market Drivers
4/30/2026 to 8/18/2026| Return | Correlation | |
|---|---|---|
| OMCL | -13.2% | |
| Market (SPY) | 6.8% | 22.9% |
| Sector (XLV) | 16.3% | 31.1% |
Fundamental Drivers
The -25.8% change in OMCL stock from 1/31/2026 to 8/18/2026 was primarily driven by a -62.1% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 48.50 | 35.97 | -25.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,178 | 1,247 | 5.9% |
| Net Income Margin (%) | 1.7% | 3.1% | 85.3% |
| P/E Multiple | 110.9 | 42.0 | -62.1% |
| Shares Outstanding (Mil) | 46 | 46 | -0.2% |
| Cumulative Contribution | -25.8% |
Market Drivers
1/31/2026 to 8/18/2026| Return | Correlation | |
|---|---|---|
| OMCL | -25.8% | |
| Market (SPY) | 11.2% | 28.4% |
| Sector (XLV) | 10.1% | 22.8% |
Fundamental Drivers
The 16.0% change in OMCL stock from 7/31/2025 to 8/18/2026 was primarily driven by a 68.1% change in the company's Net Income Margin (%).| (LTM values as of) | 7312025 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.01 | 35.97 | 16.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,136 | 1,247 | 9.8% |
| Net Income Margin (%) | 1.9% | 3.1% | 68.1% |
| P/E Multiple | 68.2 | 42.0 | -38.5% |
| Shares Outstanding (Mil) | 47 | 46 | 2.2% |
| Cumulative Contribution | 16.0% |
Market Drivers
7/31/2025 to 8/18/2026| Return | Correlation | |
|---|---|---|
| OMCL | 16.0% | |
| Market (SPY) | 22.4% | 27.5% |
| Sector (XLV) | 31.8% | 19.7% |
Fundamental Drivers
The -43.0% change in OMCL stock from 7/31/2023 to 8/18/2026 was primarily driven by a -41.1% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8182026 | Change |
|---|---|---|---|
| Stock Price ($) | 63.15 | 35.97 | -43.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,268 | 1,247 | -1.7% |
| P/S Multiple | 2.2 | 1.3 | -41.1% |
| Shares Outstanding (Mil) | 45 | 46 | -1.6% |
| Cumulative Contribution | -43.0% |
Market Drivers
7/31/2023 to 8/18/2026| Return | Correlation | |
|---|---|---|
| OMCL | -43.0% | |
| Market (SPY) | 73.6% | 23.1% |
| Sector (XLV) | 32.5% | 23.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OMCL Return | 50% | -72% | -25% | 18% | 2% | -20% | -70% |
| Peers Return | 13% | 13% | 11% | 7% | 15% | 14% | 100% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| OMCL Win Rate | 58% | 25% | 50% | 42% | 50% | 50% | |
| Peers Win Rate | 53% | 53% | 58% | 55% | 58% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OMCL Max Drawdown | -10% | -74% | -61% | -32% | -46% | -37% | |
| Peers Max Drawdown | -15% | -25% | -20% | -19% | -25% | -25% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BDX, BAX, MCK, CAH, SYK. See OMCL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/18/2026 (YTD)
How Low Can It Go
| Event | OMCL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -38.6% | -18.8% |
| % Gain to Breakeven | 62.9% | 23.1% |
| Time to Breakeven | 210 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -37.4% | -33.7% |
| % Gain to Breakeven | 59.7% | 50.9% |
| Time to Breakeven | 223 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -16.9% | -19.2% |
| % Gain to Breakeven | 20.3% | 23.8% |
| Time to Breakeven | 46 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -18.1% | -3.7% |
| % Gain to Breakeven | 22.1% | 3.9% |
| Time to Breakeven | 102 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -26.7% | -12.2% |
| % Gain to Breakeven | 36.5% | 13.9% |
| Time to Breakeven | 118 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -21.4% | -17.9% |
| % Gain to Breakeven | 27.3% | 21.8% |
| Time to Breakeven | 24 days | 123 days |
In The Past
Omnicell's stock fell -38.6% during the 2025 US Tariff Shock. Such a loss loss requires a 62.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OMCL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -38.6% | -18.8% |
| % Gain to Breakeven | 62.9% | 23.1% |
| Time to Breakeven | 210 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -37.4% | -33.7% |
| % Gain to Breakeven | 59.7% | 50.9% |
| Time to Breakeven | 223 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -26.7% | -12.2% |
| % Gain to Breakeven | 36.5% | 13.9% |
| Time to Breakeven | 118 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -21.4% | -17.9% |
| % Gain to Breakeven | 27.3% | 21.8% |
| Time to Breakeven | 24 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -75.5% | -53.4% |
| % Gain to Breakeven | 309.0% | 114.4% |
| Time to Breakeven | 1814 days | 1085 days |
In The Past
Omnicell's stock fell -38.6% during the 2025 US Tariff Shock. Such a loss loss requires a 62.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Omnicell (OMCL)
Omnicell (OMCL) is a healthcare technology company that provides comprehensive medication management solutions and adherence tools for healthcare systems and pharmacies globally. The company's core mission is to automate and optimize the entire medication use process, from storage and dispensing to patient adherence. This focus aims to enhance efficiency, improve patient safety, and drive better outcomes within diverse healthcare environments.
Omnicell's product portfolio features a range of automation technologies. For acute care settings, it offers point-of-care solutions like the XT Series automated dispensing systems, which manage medications and supplies in nursing units and operating rooms. Central pharmacies benefit from sophisticated systems such as the XR2 Automated Central Pharmacy System, IV compounding robots, and advanced inventory and controlled substance management software. These solutions are designed to integrate seamlessly with a healthcare facility's existing information management systems, streamlining clinician workflows and reducing manual errors.
Beyond acute care, Omnicell also addresses medication adherence with single-dose automation solutions that fill and label patient-specific blister packaging. It provides automated and semi-automated filling equipment for institutional pharmacies, along with packaging supplies to support medication adherence in non-acute care settings. Additionally, the company offers the EnlivenHealth Patient Engagement platform, a suite of web-based solutions, further solidifying its role as a comprehensive partner for medication management across the healthcare continuum.
AI Analysis | Feedback
Here are 1-2 brief analogies for Omnicell (OMCL):
- Amazon for hospital pharmacies: Just as Amazon automates its vast warehouses and logistics to efficiently store, retrieve, and deliver products, Omnicell provides the automated systems and robotics to manage, store, and dispense medications within hospitals and pharmacies.
- The SAP for hospital medication management: Similar to how SAP provides enterprise software to manage complex business processes, inventory, and supply chains for large companies, Omnicell offers comprehensive software and automated systems specifically designed to optimize medication inventory, workflow, and dispensing for healthcare facilities.
AI Analysis | Feedback
- Point of Care Automation Solutions: Improve clinician workflows for medication management in patient care areas.
- XT Series Automated Dispensing Systems: Automated systems for dispensing medications and supplies in nursing units and operating rooms.
- Omnicell Interface Software: Integrates Omnicell products with a healthcare facility's existing information management systems.
- Robotic Dispensing Systems: Automate the stocking and retrieval of boxed medications within pharmacies.
- Central Pharmacy Automation Solutions: Systems like the XR2 for automated storage and retrieval of medications in central pharmacies.
- IV Compounding Robots & Workflow Management Systems: Automate and manage the process of preparing intravenous medications.
- Inventory Management Software: Software for tracking and managing medication inventory within healthcare facilities.
- Controlled Substance Management Systems: Specialized systems for secure tracking and management of controlled substances.
- Single-Dose Automation Solutions: Systems that fill and label patient-specific, single-dose medication blister packaging.
- Automated Packaging Equipment: Fully and semi-automated equipment for packaging medications in institutional pharmacies.
- Medication Blister Card Packaging & Supplies: Materials and supplies to create medication blister cards for adherence in non-acute care settings.
- EnlivenHealth Patient Engagement: A web-based suite of solutions designed to enhance patient engagement.
AI Analysis | Feedback
Omnicell (OMCL) primarily sells its medication management solutions and adherence tools to other companies within the healthcare sector. Based on the company description, its major customers fall into the following categories:
- Healthcare Systems: This includes hospitals, integrated delivery networks, and other large healthcare facilities that utilize Omnicell's point-of-care automation solutions, automated dispensing systems for medications and supplies, interface software, and robotic dispensing systems to improve clinician workflows and manage medication.
- Pharmacies: This category encompasses various types of pharmacies, including central pharmacies, institutional pharmacies (e.g., hospital pharmacies, long-term care pharmacies), and non-acute care settings. They purchase Omnicell's central pharmacy automation solutions, IV compounding robots, inventory management software, controlled substance management systems, single-dose automation solutions, and automated/semi-automated filling equipment.
AI Analysis | Feedback
null
AI Analysis | Feedback
Randall Lipps, Chairman, President, Chief Executive Officer, and Founder
Randall Lipps is the founder of Omnicell, establishing the company in 1992. His inspiration stemmed from observing inefficiencies in medical supply management during his daughter's hospitalization. Under his leadership, Omnicell has evolved from a single product offering to a comprehensive portfolio of medication management solutions across various care settings. Prior to founding Omnicell, Mr. Lipps was an Assistant Vice President of Sales and Operations for a division of American Airlines. Omnicell became a publicly traded company in August 2001.
Baird Radford, Executive Vice President, Chief Financial Officer
Baird Radford was appointed Executive Vice President and Chief Financial Officer of Omnicell, effective August 26, 2025. He brings over 30 years of experience in healthcare and technology finance. Before joining Omnicell, Mr. Radford served as Chief Financial Officer for Allakos, Inc. from April 2021 to May 2025. From January 2020 to February 2021, he was Senior Vice President of Finance at Aimmune Therapeutics Inc., a company that was acquired by Nestle Health Science. He also held the role of Chief Financial Officer at HeartFlow, Inc., an AI health-tech company, from July 2014 to January 2020, where he helped raise significant capital. Earlier in his career, Mr. Radford held leadership positions at Intuitive Surgical, Inc., eBay Inc. (including Vice President of European Finance, and Vice President Corporate Controller and Chief Accounting Officer), and began his professional career at PricewaterhouseCoopers.
Nnamdi Njoku, Executive Vice President, Chief Operating Officer
Nnamdi Njoku serves as the Executive Vice President and Chief Operating Officer at Omnicell.
Corey Manley, Executive Vice President, Chief Legal and Administrative Officer
Corey Manley is the Executive Vice President, Chief Legal and Administrative Officer at Omnicell.
Perry Genova, Senior Vice President, Chief Technology Officer
Perry Genova holds the position of Senior Vice President and Chief Technology Officer at Omnicell.
AI Analysis | Feedback
Here are the key risks to Omnicell's business:
1. Intense Competition and the Shift Towards Integrated Healthcare Platforms
Omnicell faces significant competitive pressure due to the healthcare industry's increasing shift towards integrated Electronic Health Record (EHR) systems offered by major players like Oracle Health (formerly Cerner) and Epic Systems. While Omnicell provides specialized "best-of-breed" medication management solutions, these EHR titans are expanding their platforms to include pharmacy and medication administration modules, which directly threaten Omnicell's core offerings and could potentially commoditize its hardware. Furthermore, large, diversified medical technology and distribution companies such as Becton, Dickinson and Company (BDX) and Baxter International (BAX) pose substantial threats due to their extensive resources, economies of scale, and ability to bundle integrated solutions for hospitals. Omnicell's ability to out-innovate and outperform these larger competitors within its niche, particularly with its "fully autonomous pharmacy" vision, requires significant capital investment and flawless operational execution.2. Financial Performance Challenges, Including Declining Profitability and Debt Obligations
Omnicell has experienced disappointing long-term revenue growth, which has been below the healthcare sector average. The company's adjusted operating margin has significantly decreased, indicating rising costs that it has struggled to pass on to customers, thereby impacting overall profitability. Concurrently, its earnings per share (EPS) have declined even as revenue grew, suggesting a reduction in per-share profitability as the company expanded. Additionally, Omnicell carries "substantial debt obligations," including $569 million in convertible senior notes due in September 2025, which could constrain its future growth and operational flexibility. A decrease in capital investments within the healthcare industry, driven by increased operating and labor costs, has also contributed to weakened sales and profit margins for Omnicell.3. Regulatory and Cybersecurity Risks
Operating in the highly regulated healthcare industry, Omnicell is subject to stringent regulations concerning healthcare, privacy, data protection, and information security. Changes to government programs, such as the 340B Program, could adversely affect the company's financial performance. Furthermore, increasing regulatory scrutiny and the ever-present threat of cybersecurity breaches, alongside the risks associated with transitioning to cloud-based models, pose a threat to profit growth and Omnicell's long-term competitive positioning.AI Analysis | Feedback
null
AI Analysis | Feedback
Omnicell, Inc. (OMCL) operates in several key addressable markets for its medication management solutions and adherence tools.
The company itself has indicated a substantial total addressable market (TAM) for its solutions. As of September 2022, Omnicell revised its TAM estimate to over $90 billion, encompassing its offerings across the continuum of care. This was an increase from a previous estimate of $70 billion.
For its main product and service categories, the addressable markets are sized as follows:
- Pharmacy Automation: The global pharmacy automation market was valued at approximately USD 6.93 billion in 2025 and is projected to grow to about USD 17.75 billion by 2035, at a compound annual growth rate (CAGR) of 9.86% from 2026 to 2035. North America is a significant region in this market, holding approximately 41% of the revenue share in 2025. Another estimate places the global pharmacy automation market at USD 6.99 billion in 2025, expected to reach around USD 18.34 billion by 2035, with a CAGR of 10.12% from 2026 to 2035.
- Medication Management Systems: The global medication management system market size was estimated at USD 7.70 billion in 2024 and is projected to reach USD 12.79 billion by 2030, growing at a CAGR of 8.8%. North America leads this market, accounting for approximately 43.83% of the revenue share in 2024. Other reports indicate the global market was valued at USD 16.3 billion in 2023, with a projection to reach USD 30.7 billion by 2032, exhibiting a CAGR of 7.29% from 2024 to 2032.
- Point-of-Care (POC) Automation Solutions: The global point-of-care data management software market, relevant to Omnicell's point-of-care automation solutions, was valued at USD 869.3 million in 2024 and is estimated to grow to USD 2,069.1 million by 2033, with a CAGR of 10.12% during 2025-2033. North America holds a dominant position in this market, with over 42.0% market share in 2024. More broadly, the global point of care diagnostics market was valued at USD 32.87 billion in 2025 and is projected to reach USD 60.36 billion by 2034, growing at a CAGR of 7.26%. In this segment, North America held a 35.6% market share in 2025.
- Patient Engagement Solutions (EnlivenHealth Patient Engagement): The global patient engagement solutions market was valued at USD 33.95 billion in 2025 and is projected to reach USD 194.18 billion by 2034, demonstrating a significant CAGR of 21.38% during the forecast period. Another report estimates the global patient engagement solutions market size to be USD 26.36 billion in 2025, with an anticipated growth to USD 89.26 billion by 2034, at a CAGR of 14.59%. North America accounts for the largest share of this market, with approximately 40% of the revenue.
AI Analysis | Feedback
Omnicell, Inc. (OMCL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market improvements:
- New Product Launches and Upgrade Cycles (Titan XT, XTExtend, XT Amplify): The company anticipates significant revenue generation from the ongoing transition and upgrade cycle to its next-generation automated dispensing systems, particularly the new Titan XT and the broader XT Amplify innovation program, which includes XTExtend. This transition is projected to create a multi-year hardware replacement opportunity exceeding $2.5 billion. Management has highlighted strong demand for these connected devices.
- Growth in Annual Recurring Revenue (ARR) and Software-as-a-Service (SaaS) Offerings via Omnisphere: A strategic focus for Omnicell is to expand its annual recurring revenue (ARR) and accelerate its cloud-native Omnisphere technology platform. Omnisphere aims to unify all Omnicell products under a single infrastructure, offering enterprise-wide visibility into medication and supply inventory. This shift is expected to increase subscription-based revenues and enhance business predictability and margins over time. Omnicell's ARR exited Q4 2025 at an annualized run rate of $636 million, representing a 10% increase from 2024.
- Improving Healthcare System Capital Budgets and Alleviation of Labor Constraints: After experiencing a challenging environment for health system customers in 2023 and 2024 due to capital budget and labor constraints, Omnicell anticipates an improvement in these conditions. This expected alleviation of pressures is projected to lead to increased customer spending on medication management solutions, allowing Omnicell to capture incremental market share.
AI Analysis | Feedback
Share Repurchases
- Omnicell's Board of Directors approved a new $75 million stock repurchase program on May 22, 2025.
- As of March 31, 2025, there was $2.7 million remaining under a previously authorized 2016 Repurchase Program.
Outbound Investments
- In October 2025, Omnicell acquired ANiGENT to enhance its drug diversion detection capabilities and broaden its recurring revenue streams, aligning with a strategic shift towards software and services.
Peer Outperformance in Health Care Technology
OMCL has trailed 53% of its 19 Health Care Technology peers over 5Y. Health Care Technology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Health Care Technology constituents that OMCL has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
79%
of 34 industry peers · 13.8% return
3Y
65%
of 26 industry peers · -38.5% return
5Y
47%
of 19 industry peers · -76.0% return
No Health Care Technology peer with a comparable growth profile has beaten OMCL by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Technology is OMCL's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.7% | 79.7% | 140.2% | CAH 411% · MCK 348% · COR 179% |
| Health Care Services | 20 | 20.0% | 41.9% | 9.5% | HIMS 302% · RDNT 143% · DGX 72% |
| Managed Health Care | 8 | 33.2% | -3.6% | 1.3% | OSCR 142% · HQY 64% · ELV 14% |
| Health Care Facilities | 24 | 11.9% | -3.3% | -15.7% | THC 289% · NHC 263% · ENSG 132% |
| Health Care Equipment | 51 | -2.3% | -9.2% | -18.9% | POCI 10738% · UFPT 396% · GKOS 288% |
| Health Care Supplies | 12 | 38.3% | -12.4% | -27.5% | LNTH 314% · HAE 81% · MMSI 31% |
| Pharmaceuticals | 63 | 3.1% | -1.7% | -31.9% | LQDA 2959% · INDV 1388% · ETON 1385% |
| Life Sciences Tools & Services | 108 | -8.4% | -32.7% | -70.6% | SNWV 1953% · ELMD 259% · MEDP 235% |
| Health Care Technology ← | 20 | -28.4% | -53.8% | -73.9% | SPOK 37% · HSTM -2% · VEEV -24% |
| Biotechnology | 365 | 6.6% | -27.4% | -77.2% | BRTX 106400% · DNTH 1803% · CELZ 1443% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 207.88 |
| Mkt Cap | 52.2 |
| Rev LTM | 24,544 |
| Op Inc LTM | 3,258 |
| FCF LTM | 3,517 |
| FCF 3Y Avg | 2,988 |
| CFO LTM | 4,218 |
| CFO 3Y Avg | 3,632 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.7% |
| Rev Chg 3Y Avg | 7.4% |
| Rev Chg Q | 6.6% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 31.4% |
| Op Inc Chg 3Y Avg | 19.0% |
| Op Mgn LTM | 3.2% |
| Op Mgn 3Y Avg | 2.9% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 12.8% |
| CFO/Rev 3Y Avg | 12.7% |
| FCF/Rev LTM | 8.6% |
| FCF/Rev 3Y Avg | 8.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 52.2 |
| P/S | 1.2 |
| P/Op Inc | 19.9 |
| P/EBIT | 20.6 |
| P/E | 33.0 |
| P/CFO | 12.8 |
| Total Yield | 4.0% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 5.6% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.5% |
| 3M Rtn | 15.9% |
| 6M Rtn | -0.2% |
| 12M Rtn | 17.3% |
| 3Y Rtn | 6.0% |
| 1M Excs Rtn | 1.0% |
| 3M Excs Rtn | 11.1% |
| 6M Excs Rtn | -12.6% |
| 12M Excs Rtn | -2.4% |
| 3Y Excs Rtn | -68.6% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Connected devices, software licenses, and other | 565 | 539 | 624 | 828 | 739 |
| Technical services | 260 | 238 | 226 | 207 | 207 |
| Software as a Service (SaaS) and Expert Services | 259 | 244 | 213 | 186 | 113 |
| Consumables | 100 | 91 | 85 | 75 | 73 |
| Total | 1,185 | 1,112 | 1,147 | 1,296 | 1,132 |
| $ Mil | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|
| Automation and Analytics | 148 | 88 | 84 | 104 | 48 |
| Medication Adherence | -6 | -2 | 6 | 5 | 2 |
| Corporate costs | -98 | -81 | -84 | ||
| Corporate | -61 | ||||
| Total | 44 | 6 | 6 | 49 | 50 |
| $ Mil | 2013 | 2012 |
|---|---|---|
| Acute Care | 263 | 235 |
| Non-Acute Care | 229 | 207 |
| Total | 493 | 442 |
Price Behavior
Price Behavior
| Market Price | $35.97 | |
| Market Cap ($ Bil) | 1.6 | |
| First Trading Date | 08/09/2001 | |
| Distance from 52W High | -30.0% | |
| 50 Days | 200 Days | |
| DMA Price | $40.38 | $40.75 |
| DMA Trend | up | down |
| Distance from DMA | -10.9% | -11.7% |
| 3M | 1YR | |
| Volatility | 48.1% | 50.6% |
| Downside Capture | 145.70 | 109.24 |
| Upside Capture | 29.52 | 100.88 |
| Correlation (SPY) | 22.0% | 26.4% |
OMCL Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.01 | 0.54 | 0.62 | 1.11 | 1.02 | 0.80 |
| Up Beta | -6.86 | -0.70 | -0.37 | 0.06 | 0.55 | 0.88 |
| Down Beta | 2.37 | 1.76 | 1.62 | 2.15 | 1.68 | 0.90 |
| Up Capture | -156% | -31% | 8% | 69% | 96% | 22% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 11 | 20 | 32 | 64 | 132 | 357 |
| Down Capture | 79% | 106% | 95% | 149% | 97% | 97% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 11 | 23 | 31 | 62 | 119 | 391 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMCL | |
|---|---|---|---|---|
| OMCL | 13.6% | 50.5% | 0.42 | - |
| Sector ETF (XLV) | 26.3% | 15.5% | 1.31 | 20.5% |
| Equity (SPY) | 20.4% | 12.8% | 1.17 | 26.3% |
| Gold (GLD) | 29.8% | 28.5% | 0.91 | 4.3% |
| Commodities (DBC) | 40.2% | 20.2% | 1.56 | -10.2% |
| Real Estate (VNQ) | 13.1% | 13.9% | 0.65 | 26.3% |
| Bitcoin (BTCUSD) | -45.4% | 42.7% | -1.30 | 20.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMCL | |
|---|---|---|---|---|
| OMCL | -24.7% | 50.9% | -0.37 | - |
| Sector ETF (XLV) | 6.6% | 15.0% | 0.25 | 28.0% |
| Equity (SPY) | 13.1% | 17.2% | 0.59 | 33.0% |
| Gold (GLD) | 19.8% | 18.6% | 0.87 | 4.4% |
| Commodities (DBC) | 9.8% | 19.6% | 0.39 | 2.0% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.02 | 34.6% |
| Bitcoin (BTCUSD) | 7.1% | 52.6% | 0.32 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMCL | |
|---|---|---|---|---|
| OMCL | -0.3% | 44.2% | 0.15 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.51 | 36.4% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 39.8% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 3.1% |
| Commodities (DBC) | 7.8% | 18.1% | 0.35 | 9.9% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 35.7% |
| Bitcoin (BTCUSD) | 59.9% | 66.0% | 1.00 | 13.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | -10.4% | -10.2% | |
| 4/28/2026 | 20.9% | 15.4% | 14.6% |
| 2/5/2026 | -16.3% | -19.0% | -11.5% |
| 10/30/2025 | 13.6% | 20.9% | 22.2% |
| 7/31/2025 | 4.4% | 4.7% | 12.1% |
| 5/6/2025 | -15.8% | -9.9% | 2.6% |
| 2/6/2025 | -11.2% | -8.8% | -16.7% |
| 10/30/2024 | 32.2% | 24.1% | 20.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 14 |
| # Negative | 10 | 11 | 9 |
| Median Positive | 4.8% | 5.9% | 13.3% |
| Median Negative | -10.8% | -10.2% | -10.0% |
| Max Positive | 33.0% | 33.7% | 54.9% |
| Max Negative | -34.5% | -36.7% | -33.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | -10.4% | -10.2% | |
| 4/28/2026 | 20.9% | 15.4% | 14.6% |
| 2/5/2026 | -16.3% | -19.0% | -11.5% |
| 10/30/2025 | 13.6% | 20.9% | 22.2% |
| 7/31/2025 | 4.4% | 4.7% | 12.1% |
| 5/6/2025 | -15.8% | -9.9% | 2.6% |
| 2/6/2025 | -11.2% | -8.8% | -16.7% |
| 10/30/2024 | 32.2% | 24.1% | 20.8% |
| 8/1/2024 | 33.0% | 33.7% | 54.9% |
| 5/2/2024 | 7.8% | 10.3% | 19.9% |
| 2/8/2024 | -10.4% | -14.6% | -12.0% |
| 11/2/2023 | -18.3% | -13.6% | -5.5% |
| 8/1/2023 | 4.7% | 4.2% | -6.7% |
| 5/2/2023 | 14.5% | 12.0% | 24.7% |
| 2/28/2023 | 5.0% | -1.4% | 2.0% |
| 11/2/2022 | -34.5% | -36.7% | -33.3% |
| 8/4/2022 | -1.4% | -1.4% | -10.0% |
| 4/28/2022 | 1.6% | 4.6% | 5.2% |
| 2/14/2022 | -5.5% | -15.3% | -7.4% |
| 11/2/2021 | 0.5% | 3.0% | 1.1% |
| 7/29/2021 | -4.3% | 0.7% | 4.4% |
| 4/29/2021 | 0.8% | -2.8% | -3.4% |
| 2/1/2021 | 3.3% | 5.9% | 2.8% |
| 10/27/2020 | 0.5% | 4.6% | 24.8% |
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 14 |
| # Negative | 10 | 11 | 9 |
| Median Positive | 4.8% | 5.9% | 13.3% |
| Median Negative | -10.8% | -10.2% | -10.0% |
| Max Positive | 33.0% | 33.7% | 54.9% |
| Max Negative | -34.5% | -36.7% | -33.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/04/2021 | 10-Q |
| 12/31/2020 | 02/24/2021 | 10-K |
| 09/30/2020 | 10/30/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/26/2020 | 10-K |
| 09/30/2019 | 11/01/2019 | 10-Q |
Recent Forward Guidance
Updated 7/31/2026Latest: Q2 2026 Earnings Reported 7/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Product Bookings | 425.00 Mil | 492.50 Mil | 560.00 Mil | -7.9% | Lowered | Guidance: 535.00 Mil for 2026 | |
| 2026 Annual Recurring Revenue | 660.00 Mil | 670.00 Mil | 680.00 Mil | -2.9% | Lowered | Guidance: 690.00 Mil for 2026 | |
| Q3 2026 Total Revenues | 301.00 Mil | 304.00 Mil | 307.00 Mil | -1.9% | Lowered | Guidance: 310.00 Mil for Q2 2026 | |
| 2026 Total Revenues | 1.23 Bil | 1.24 Bil | 1.25 Bil | 0 | Affirmed | Guidance: 1.24 Bil for 2026 | |
| Q3 2026 Product Revenues | 169.00 Mil | 170.50 Mil | 172.00 Mil | -2.8% | Lowered | Guidance: 175.50 Mil for Q2 2026 | |
| 2026 Product Revenues | 690.00 Mil | 695.00 Mil | 700.00 Mil | -0.7% | Lowered | Guidance: 700.00 Mil for 2026 | |
| Q3 2026 Service Revenues | 132.00 Mil | 133.50 Mil | 135.00 Mil | -0.7% | Lowered | Guidance: 134.50 Mil for Q2 2026 | |
| 2026 Service Revenues | 535.00 Mil | 540.00 Mil | 545.00 Mil | 0.9% | Raised | Guidance: 535.00 Mil for 2026 | |
| 2026 Technical Services Revenues | 267.00 Mil | 269.50 Mil | 272.00 Mil | 1.7% | Raised | Guidance: 265.00 Mil for 2026 | |
| 2026 SaaS and Expert Service Revenues | 268.00 Mil | 270.50 Mil | 273.00 Mil | 0.2% | Raised | Guidance: 270.00 Mil for 2026 | |
| Q3 2026 Non-GAAP EBITDA | 32.00 Mil | 34.50 Mil | 37.00 Mil | -12.7% | Lowered | Guidance: 39.50 Mil for Q2 2026 | |
| 2026 Non-GAAP EBITDA | 175.00 Mil | 180.00 Mil | 185.00 Mil | 12.1% | Raised | Guidance: 160.50 Mil for 2026 | |
| Q3 2026 Non-GAAP Earnings Per Share | 0.35 | 0.39 | 0.43 | -11.4% | Lowered | Guidance: 0.44 for Q2 2026 | |
| 2026 Non-GAAP Earnings Per Share | 2.15 | 2.23 | 2.3 | 17.1% | Raised | Guidance: 1.9 for 2026 | |
Prior: Q1 2026 Earnings Reported 4/28/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Product Bookings | 510.00 Mil | 535.00 Mil | 560.00 Mil | 0 | Affirmed | Guidance: 535.00 Mil for 2026 | |
| 2026 Annual Recurring Revenue | 680.00 Mil | 690.00 Mil | 700.00 Mil | 0 | Affirmed | Guidance: 690.00 Mil for 2026 | |
| Q2 2026 Revenue | 307.00 Mil | 310.00 Mil | 313.00 Mil | 1.6% | Higher New | Guidance: 305.00 Mil for Q1 2026 | |
| 2026 Revenue | 1.22 Bil | 1.24 Bil | 1.25 Bil | 0 | Affirmed | Guidance: 1.24 Bil for 2026 | |
| Q2 2026 Product Revenues | 174.00 Mil | 175.50 Mil | 177.00 Mil | 1.2% | Higher New | Guidance: 173.50 Mil for Q1 2026 | |
| 2026 Product Revenues | 690.00 Mil | 700.00 Mil | 710.00 Mil | 0 | Affirmed | Guidance: 700.00 Mil for 2026 | |
| Q2 2026 Service Revenues | 133.00 Mil | 134.50 Mil | 136.00 Mil | 2.3% | Higher New | Guidance: 131.50 Mil for Q1 2026 | |
| 2026 Service Revenues | 525.00 Mil | 535.00 Mil | 545.00 Mil | 0 | Affirmed | Guidance: 535.00 Mil for 2026 | |
| 2026 Technical Services Revenues | 260.00 Mil | 265.00 Mil | 270.00 Mil | 0 | Affirmed | Guidance: 265.00 Mil for 2026 | |
| 2026 SaaS and Expert Service Revenues | 265.00 Mil | 270.00 Mil | 275.00 Mil | 0 | Affirmed | Guidance: 270.00 Mil for 2026 | |
| Q2 2026 Non-GAAP EBITDA | 37.00 Mil | 39.50 Mil | 42.00 Mil | 31.7% | Higher New | Guidance: 30.00 Mil for Q1 2026 | |
| 2026 Non-GAAP EBITDA | 153.00 Mil | 160.50 Mil | 168.00 Mil | 5.2% | Raised | Guidance: 152.50 Mil for 2026 | |
| Q2 2026 EPS | 0.4 | 0.44 | 0.48 | 41.9% | Higher New | Guidance: 0.31 for Q1 2026 | |
| 2026 EPS | 1.8 | 1.9 | 2 | 8.6% | Raised | Guidance: 1.75 for 2026 | |
Q4 2025 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Total Revenues | 300.00 Mil | 305.00 Mil | 310.00 Mil | -1.9% | Lower New | Guidance: 311.00 Mil for Q4 2025 | |
| Q1 2026 Product Revenues | 171.00 Mil | 173.50 Mil | 176.00 Mil | -2.3% | Lower New | Guidance: 177.50 Mil for Q4 2025 | |
| Q1 2026 Service Revenues | 129.00 Mil | 131.50 Mil | 134.00 Mil | -1.5% | Lower New | Guidance: 133.50 Mil for Q4 2025 | |
| Q1 2026 Non-GAAP EBITDA | 27.00 Mil | 30.00 Mil | 33.00 Mil | -25.0% | Lower New | Guidance: 40.00 Mil for Q4 2025 | |
| Q1 2026 EPS | 0.26 | 0.31 | 0.36 | -31.1% | Lower New | Guidance: 0.45 for Q4 2025 | |
| 2026 Product Bookings | 510.00 Mil | 535.00 Mil | 560.00 Mil | 1.9% | Higher New | Guidance: 525.00 Mil for 2025 | |
| 2026 Annual Recurring Revenue | 680.00 Mil | 690.00 Mil | 700.00 Mil | 11.3% | Higher New | Guidance: 620.00 Mil for 2025 | |
| 2026 Total Revenues | 1.22 Bil | 1.24 Bil | 1.25 Bil | 4.5% | Higher New | Guidance: 1.18 Bil for 2025 | |
| 2026 Product Revenues | 690.00 Mil | 700.00 Mil | 710.00 Mil | 5.5% | Higher New | Guidance: 663.50 Mil for 2025 | |
| 2026 Service Revenues | 525.00 Mil | 535.00 Mil | 545.00 Mil | 3.2% | Higher New | Guidance: 518.50 Mil for 2025 | |
| 2026 Technical Services Revenues | 260.00 Mil | 265.00 Mil | 270.00 Mil | 1.9% | Higher New | Guidance: 260.00 Mil for 2025 | |
| 2026 SaaS and Expert Service Revenues | 265.00 Mil | 270.00 Mil | 275.00 Mil | 4.4% | Higher New | Guidance: 258.50 Mil for 2025 | |
| 2026 Non-GAAP EBITDA | 145.00 Mil | 152.50 Mil | 160.00 Mil | 6.6% | Higher New | Guidance: 143.00 Mil for 2025 | |
| 2026 EPS | 1.65 | 1.75 | 1.85 | 4.2% | Higher New | Guidance: 1.68 for 2025 | |
Q3 2025 Earnings Reported 10/30/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Total Revenues | 306.00 Mil | 311.00 Mil | 316.00 Mil | ||||
| Q4 2025 Product Revenues | 175.00 Mil | 177.50 Mil | 180.00 Mil | ||||
| Q4 2025 Service Revenues | 131.00 Mil | 133.50 Mil | 136.00 Mil | ||||
| Q4 2025 Non-GAAP EBITDA | 37.00 Mil | 40.00 Mil | 43.00 Mil | ||||
| Q4 2025 Non-GAAP Earnings Per Share | 0.4 | 0.45 | 0.5 | ||||
| 2025 Product Bookings | 500.00 Mil | 525.00 Mil | 550.00 Mil | 0 | Affirmed | Guidance: 525.00 Mil for 2025 | |
| 2025 Annual Recurring Revenue | 610.00 Mil | 620.00 Mil | 630.00 Mil | 0 | Affirmed | Guidance: 620.00 Mil for 2025 | |
| 2025 Total Revenues | 1.18 Bil | 1.18 Bil | 1.19 Bil | 3.2% | Raised | Guidance: 1.15 Bil for 2025 | |
| 2025 Product Revenues | 661.00 Mil | 663.50 Mil | 666.00 Mil | 4.9% | Raised | Guidance: 632.50 Mil for 2025 | |
| 2025 Service Revenues | 516.00 Mil | 518.50 Mil | 521.00 Mil | 1.2% | Raised | Guidance: 512.50 Mil for 2025 | |
| 2025 Technical Services Revenues | 259.00 Mil | 260.00 Mil | 261.00 Mil | 5.1% | Raised | Guidance: 247.50 Mil for 2025 | |
| 2025 SaaS and Expert Service Revenues | 257.00 Mil | 258.50 Mil | 260.00 Mil | -2.5% | Lowered | Guidance: 265.00 Mil for 2025 | |
| 2025 Non-GAAP EBITDA | 140.00 Mil | 143.00 Mil | 146.00 Mil | 4.0% | Raised | Guidance: 137.50 Mil for 2025 | |
| 2025 Non-GAAP Earnings Per Share | 1.63 | 1.68 | 1.73 | 10.2% | Raised | Guidance: 1.52 for 2025 | |
Insider Activity
Updated 8/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Njoku, Nnamdi | President & COO | Direct | Sell | 8182026 | 36.85 | 3,083 | 113,609 | 5,941,088 | Form |
| 2 | Lipps, Randall A | CHAIRMAN, CEO | In Trust with Wife | Sell | 7172026 | 47.00 | 10,000 | 470,000 | 16,255,467 | Form |
| 3 | Njoku, Nnamdi | EVP, Chief Operating Officer | Direct | Sell | 5192026 | 43.22 | 3,090 | 133,550 | 6,689,827 | Form |
| 4 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 5192026 | 43.22 | 5,025 | 217,180 | 4,874,496 | Form |
| 5 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 3172026 | 34.69 | 7,405 | 256,879 | 3,355,124 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Njoku, Nnamdi | President & COO | Direct | Sell | 8182026 | 36.85 | 3,083 | 113,609 | 5,941,088 | Form |
| 2 | Lipps, Randall A | CHAIRMAN, CEO | In Trust with Wife | Sell | 7172026 | 47.00 | 10,000 | 470,000 | 16,255,467 | Form |
| 3 | Njoku, Nnamdi | EVP, Chief Operating Officer | Direct | Sell | 5192026 | 43.22 | 3,090 | 133,550 | 6,689,827 | Form |
| 4 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 5192026 | 43.22 | 5,025 | 217,180 | 4,874,496 | Form |
| 5 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 3172026 | 34.69 | 7,405 | 256,879 | 3,355,124 | Form |
| 6 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 2182026 | 36.59 | 4,243 | 155,251 | 3,128,311 | Form |
| 7 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 1122026 | 49.90 | 6,106 | 304,689 | 4,574,533 | Form |
| 8 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 12172025 | 43.30 | 278 | 12,037 | 4,233,874 | Form |
| 9 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 12052025 | 39.90 | 6,106 | 243,629 | 3,921,452 | Form |
| 10 | Lipps, Randall A | CHAIRMAN, PRESIDENT AND CEO | Direct | Sell | 12032025 | 35.97 | 28,250 | 1,016,093 | 13,906,917 | Form |
| 11 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 11182025 | 34.90 | 3,473 | 121,208 | 3,643,141 | Form |
| 12 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 9162025 | 33.25 | 3,880 | 129,010 | 3,679,212 | Form |
Investor Activity (13F)
Updated Aug 19, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/18/2026